Skip to main content

Octreotide Injection

Last Updated: January 25, 2023
Status: Current

Products Affected - Description
    • Sandostatin injection, Novartis, 100 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0181-01
    • Sandostatin injection, Novartis, 50 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0180-01
    • Sandostatin injection, Novartis, 500 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0182-01
    • Octreotide Acetate injection, Avet Pharmaceuticals, 100 mcg/mL, 1 mL vial, 10 count, NDC 23155-0688-41
    • Octreotide Acetate injection, Avet Pharmaceuticals, 1000 mcg/mL, 5 mL vial, 1 count, NDC 23155-0686-31
    • Octreotide Acetate injection, Avet Pharmaceuticals, 200 mcg/mL, 5 mL vial, 1 count, NDC 23155-0685-31
    • Octreotide Acetate injection, Avet Pharmaceuticals, 50 mcg/mL, 1 mL vial, 10 count, NDC 23155-0687-41
    • Octreotide Acetate injection, Avet Pharmaceuticals, 500 mcg/mL, 1 mL vial, 10 count, NDC 23155-0689-41
    • Octreotide Acetate injection, Fresenius Kabi, 200 mcg/mL, 5 mL vial, 1 count, NDC 63323-0378-05
    • Octreotide Acetate injection, Fresenius Kabi, 500 mcg/mL, 1 mL vial, 10 count, NDC 63323-0377-01
    • Octreotide Acetate injection, Hikma, 1,000 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6178-01
    • Octreotide Acetate injection, Hikma, 100 mcg/mL, 1 mL vial, 10 count, NDC 00641-6175-10
    • Octreotide Acetate injection, Hikma, 50 mcg/mL, 1 mL vial, 10 count, NDC 00641-6174-10
    • Octreotide Acetate injection, Hikma, 500 mcg/mL, 1 mL vial, 10 count, NDC 00641-6176-10
    • Octreotide Acetate injection, Mylan Institutional (Viatris), 50 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0239-01
    • Octreotide Acetate injection, Mylan Institutional (Viatris), 500 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0246-01
    • Octreotide Acetate injection, Sagent, 100 mcg/mL, 1 mL vial, 10 count, NDC 25021-0452-01
    • Octreotide Acetate injection, Sagent, 50 mcg/mL, 1 mL vial, 10 count, NDC 25021-0451-01
    • Octreotide Acetate injection, Sagent, 500 mcg/mL, 1 mL vial, 10 count, NDC 25021-0453-01
Reason for the Shortage
    • Avet has octreotide on shortage due to increased demand.
    • Fresenius Kabi had octreotide on shortage due to manufacturing delays.
    • Hikma did not provide a reason for the shortage.
    • Sagent discontinued octreotide 200 mcg/mL 5 mL vials and 1,000 mcg/mL 5 mL vials.
    • Sun Pharma has Bynfezia Pen available.
    • Teva discontinued octreotide in April 2022.
    • Viatris did not provide a reason for the shortage.
    • Novartis has Sandostatin available. The 200 mcg/mL 5 mL vials were discontinued in early-2018.
Available Products
    • Bynfezia Pen injection, Sun Pharma, 2,500 mcg/mL, 2.8 mL single-use pen injector, 1 count, NDC 62756-0452-36
    • Bynfezia Pen injection, Sun Pharma, 2,500 mcg/mL, 2.8 mL single-use pen injector, 2 count, NDC 62756-0452-37
    • Octreotide Acetate injection, Fresenius Kabi, 100 mcg/mL, 1 mL vial, 10 count, NDC 63323-0376-01
    • Octreotide Acetate injection, Fresenius Kabi, 1000 mcg/mL, 5 mL vial, 1 count, NDC 63323-0379-05
    • Octreotide Acetate injection, Fresenius Kabi, 50 mcg/mL, 1 mL vial, 10 count, NDC 63323-0365-01
    • Octreotide Acetate injection, Hikma, 200 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6177-01
    • Octreotide Acetate injection, Mylan Institutional (Viatris), 100 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0245-01

Estimated Resupply Dates

    • Avet has octreotide 50 mcg/mL 1 mL vials, 100 mcg/mL 1 mL vials, 500 mcg/mL 1 mL vials, 200 mcg/mL 5 mL vials, and 1,000 mcg/mL 5 mL vials on back order and the company estimates a release date of January 2023.
    • Fresenius Kabi has octreotide 500 mcg/mL 1 mL vials on back order and the company estimates a release date of late-January to early-February 2023. There are short-dated 200 mcg/mL 5 mL vials available with an expiration date of < 1 month.
    • Hikma has octreotide 500 mcg/mL 1 mL vials on allocation. The 50 mcg/mL 1 mL vials and 100 mcg/mL 1 mL vials are on back order and the company estimates a release date of late-February to early-March 2023. The 1,000 mcg/mL 5 mL vials are on back order and the company estimates a release date of late-January 2023.
    • Sagent has 50 mcg/mL 1 mL vials, 100 mcg/mL 1 mL vials, and 500 mcg/mL 1 mL vials on back order and the company cannot estimate a release date.
    • Viatris has octreotide 50 mcg/mL 1 mL syringes and 500 mcg/mL 1 mL syringes on back order and the company estimates a release date of late-February 2023.
    • Novartis has all Sandostatin presentations on back order and the company cannot estimate a release date. There is some emergency supply available.

Updated

Updated January 25, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 16, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.